Drug maker Dendreon Corp is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report. The Seattle-based company is working with JPMorgan Chase & Co to help it find a buyer, Bloomberg said, citing people familiar with the matter. Dendreon's troubles began in 2011 after the company withdrew its sales forecast for the drug.
Help employers find you! Check out all the jobs and post your resume.
